Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am glad for you man! I am in around $0.50 and it does seem like yesterday .However, it was a bumpy road wasn't it?
Remember Dr. Kim said INO should be valued around $4B right now. We are still undervalued.
World Vaccine Conference 2014
World's Largest Vaccine Conference & Expo March 24th-26th 2014 in Washington D.C.
Speakers list:
Dr. Sardesai Chief Operating Officer
Day 2 - March 25 @ 11.45 Cancer immunotherapy – Prospects for expanding the standard of care in HPV associated disease
@ 14.25 Using synthetic DNA vaccines to induce strong antibody and T-cell responses
http://www.terrapinn.com/conference/world-vaccine-congress-washington/speaker-niranjan-SARDESAI.stm
Also, Dr. Anthony Ford Hutchinson of Inovio Scientific Advisory Board is speaking.
Day 2 - March 25 @ 10.49
Chairman's remarks
Day 3 - March 26@ 11.29
Chairman's remarks @ 11.55
Use of Innovative technologies to address unmet needs for vaccines for viral diseases
http://www.terrapinn.com/conference/world-vaccine-congress-washington/speaker-anthony-FORDHUTCHINSON.stm
He can be seen in Inovio's latest video:
See below 2014 catalysts. Institutional buying is way up. People are finally catching on.
Dr. Kim has stated that partnerships are in the works. They like to announce deals at conferences. INO is presenting Monday. I think they have something new to discuss whether it be partnership, Roche milestone payments or grants.
It could also be that the CEO said INO will be the next Amgen or Gilead which would put INO between $400 and $600 per share.
Catalysts: 1st Half 2014
1. VGX-3100 results - Mid-2014 Cervical dysplasia Phase II study data
2. INO-3112 - Cervical Cancer 1H 2014 Initiate phase I/IIa
3. INO-3112 - Head and Neck Cancer 1H 2014 Initiate phase I/IIa
4. Prostate Cancer - initiate trial with Partner Roche
5. Initiate PENNVAX-GP phase I study
2014 2nd Half:
1. Initiate hTERT trials for:
a. Lung cancer
b. breast cancer
c. Pancreatic cancer
2. Initiate HEP B - initiate trial with Roche
3. Initiate Malaria trials
Other potential catalysts:
MERS, FLU, MRSA, Chikungunya virus, and Dengue fever.
That is exactly what people said 2 years ago when INO was $0.50.Longs loaded up for cheap. Many longs are up over 400%. Longs told the "naysayers", we told you so, and will so again in 2 years when it is the next Amgen or Gilead.
Get to know more about Inovio.
Fluff PRs? lol. Lowes sells their panels. I am sure that is all made up too huh...
Lowes is selling Andalay panels.
http://www.lowes.com/Search=andalay?storeId=10151&langId=-1&catalogId=10051&N=0&newSearch=true&Ntt=andalay#!
Dr. J. Joseph Kim, President and CEO, to Ring the NYSE Opening Bell®
http://www.nyse.com/about/newsevents/1391031678905.html
Inovio Pharmaceuticals Visits the New York Stock Exchange;
Dr. J. Joseph Kim, President and CEO, to Ring the NYSE Opening Bell®
For Release: 10 Feb 14
Who/What:
Executives and guests of Inovio Pharmaceuticals, Inc. will visit the New York Stock Exchange (NYSE) on Wednesday, Feb 12, 2014.
To mark the occasion, Dr. J. Joseph Kim, President & CEO, Inovio Pharmaceuticals Inc., will ring the NYSE Opening Bell.
Hi Tom. As a dog lover, I know they are basically family members, and we would do anything for them... How did they live so long, Is VGX working on something for extended life!? This treatment looks amazing. It is great to see a company I am invested in saving lives, even dogs, using pioneering technology.
I took Dr. Kim's advice when INO was at $0.55 and Dr. Kim said to buy stock that it was going to be an "epic year." I didn't take anyones technical advice and am up over 300%.
Inovio is catalyst driven. Technicals don't matter to me. They don't sell phones, but make gains on vaccine developments and progress. Next Tuesday should be a catalyst event.
So when Dr. Kim says 2014 will dwarf 2014 I trust him, not technicals.
Dr. Kim interview "We think this is the year we will establish ourselves as the leading cancer immunotherapy company."
10-4 Either way, you have good opine. I listen thanks for the tips I will check those out. But I remain long INO due to Flu, Mers season in the air,; as well as surprise announcements at any time.
Roche gave their 2013 overview this morning. Slide 33 "Immuno-oncology: Collaboration deals in 2013 MAJOR focus areas."
http://www.roche.com/irp140130-a.pdf
http://www.roche.com/investors/annual_reports.htm
http://www.roche.com/gb13e.pdf
This is either INO or we have some competition. Keep in mind that Connie Trimble, M.D., associate professor of gynecology and obstetrics, oncology and pathology at Johns Hopkins' Kimmel Cancer Center, is the Princinple Investigator of VGX-3100.
http://medicalxpress.com/news/2014-01-vaccine-cervical-precancers-triggers-immune.html
http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/cervical_dysplasia/research.html
Inovio affiliate VGX International is developing a gene therapy for obesity.
http://www.vgxi.com/bbs/bbs/board.php?bo_table=news&wr_id=341
"VGX Inter (KOSPI, 011000) today, "Industry-Academic Cooperation Foundation, Yonsei University, Seoul Paik Hospital, Inje University researchers in collaboration with the plasmid-based adiponectin (adiponectin) to develop a gene therapy of obesity and metabolic cooperation was signed a memorandum of understanding," he said . Accordingly, VGX Inter metabolism in obesity candidate gene therapy that holds the license to produce the electroporation device companies (brand name: select d) provided with, and the national authority in Obesity Research, Yonsei University, Professor of Food Science and Nutrition, Park, Tae - Seon The researchers evaluated the efficacy of animal testing is scheduled through. Clinical studies in the treatment of obesity in Korea, Seoul Paik Hospital, Inje University obesity expert gangjaeheon Center, as was the professor in charge. obesity treatment drugs on the market in 1999, the first time, many commercial products, but about 75,000 million to $ 2,019 in 2012 , approximately $ 2.6 billion expected to grow by an annual average being 20.7%. Our products include Xenical and Reductil interrupted, etc., but there are few side effects of therapeutic drug development are desperately needed a new situation. VGX Inter bakyounggeun said "existing concerns about the safety of obesity are high, but this joint research DNA drug side effects develop with less obesity, weight control, as well as to metabolic control has the advantage of being, "and" our plasmid-based technology, the domestic well-known researchers and joint research quickly to a safe and effective obesity treatment develop and improve the quality of life of individuals and is expected to contribute to public health, "he said.
Don't worry that is about to change. They are already preparing for Phase III HPV trials. In the mean time we will get more funding and partnerships. That is all according to Dr. Kim and Bernie.
"2014 will be just as dynamic and potentially transformative. We expect to initiate phase I and phase I/IIa clinical trials targeting cervical cancer, head and neck cancer, prostate cancer, breast and lung cancer, HIV and malaria. We have the prospect of additional partnerships. Importantly, we will report Inovio’s efficacy data from our phase II clinical trial targeting HPV-caused cervical dysplasias."
Email from Inovio at 1:55
Thank you for listening to Dr. Kim’s corporate presentation at Biotech Showcase 2014. 2013 was a dynamic year for Inovio. We reported and published best-in-class T-cell responses from multiple clinical studies as well as finalized a validating license deal with Roche for two of Inovio’s pre-clinical cancer products.
2014 will be just as dynamic and potentially transformative. We expect to initiate phase I and phase I/IIa clinical trials targeting cervical cancer, head and neck cancer, prostate cancer, breast and lung cancer, HIV and malaria. We have the prospect of additional partnerships. Importantly, we will report Inovio’s efficacy data from our phase II clinical trial targeting HPV-caused cervical dysplasias.
We appreciate your interest in Inovio. Please let us know if you have questions.
Best regards,
Bernie Hertel
Senior Director, Communications & IR
bhertel@inovio.com
858 336 5579
Dr. Mark Bagarazzi, Chief Medical Officer of Inovio is
Speaking Monday JAN 27th 2014 @ Washington Bioleaders Forum. "Cancer vaccines: Learning from past successes and failures to deliver game-changing efficacy"
http://www.bioleaders-forum.com/page.cfm/Action=VisitorList/ListID=2/letter=B/loadSearch=26823_326
Brochures
Vaccine Forum
http://www.bioleaders-forum.com/files/13641_phacilitate_vaccine_brochure_updates.pdf
Immunotherapy forum
http://www.bioleaders-forum.com/files/13640_phacilitate_immuno_brochure_updates_fv.pdf
Presentation link from 1/13/13. http://www.media-server.com/m/p/d9hvz9mo
Inovio's affiliate VGX.
http://www.vgxi.com/bbs/bbs/board.php?bo_table=news&wr_id=338
AE37 results this month. Wow nice volume today. And price movement. .
hahaha probably nooone.
Someone hacked the board LOL. Look at the intro pick wth is that?
AE37 news. More to come. Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
.
http://ih.advfn.com/p.php?pid=nmona&article=60608775&symbol=GNBT
I agree with you! If I lose I lose. ITs a Long shot.
A writer and AE37 patient. Follow here updates.
http://rtonj.blogspot.com/
See where she mentions "Peptide vaccine" and links to AE37 study.
http://www.huffingtonpost.com/2013/10/02/emily-helck-breast-cancer-time-lapse_n_4025890.html
Here are a couple facts for you:
Oral-Lyn is pending approval in India.
AE-37 results are coming soon.
It is funny you group all pumpers in 1 jar. Yes I am a very large shareholder so I can post my opinion. Mangement is not the best and may be incompetant. Warrant overhang is there. The stock price is atrocious. I understand longs anger but I am averaged 3 cents so I am not as mad as you guys. I believe AE37 works and can't wait to see what comes of all of this.
I find is very suspicious people have created ihub alias just to spam this board...At this point in time...GLTAL.
HEP C http://clinicaltrials.gov/ct2/show/NCT02027116?term=vgx&rank=1
To Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Chronic Hepatitis C Infection (VGX-6150-01)
This study is not yet open for participant recruitment.
Verified January 2014 by VGX International, Inc.
Sponsor:
VGX International, Inc.
Collaborator:
Inovio Pharmaceuticals
Information provided by (Responsible Party):
VGX International, Inc.
ClinicalTrials.gov Identifier:
NCT02027116
First received: January 1, 2014
Last updated: NA
Last verified: January 2014
History: No changes posted
Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
Purpose
To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients
Condition Intervention Phase
Hepatitis C, Chronic
Biological: VGX-6150
Phase 1
Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Resource links provided by NLM:
MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis C
Drug Information available for: Deoxyribonucleic acid Hepatitis A Vaccines
U.S. FDA Resources
Further study details as provided by VGX International, Inc.:
Primary Outcome Measures:
Safety and Tolerability [ Time Frame: Screening ~ week 36 ] [ Designated as safety issue: Yes ]
To evaluate the safety and tolerability of VGX-6150 as second-line therapy in chronic hepatitis C patients.
Secondary Outcome Measures:
Immunogenicity and virologic response [ Time Frame: Screening ~ Week 36 ] [ Designated as safety issue: No ]
To evaluate the immunogenicity and virologic response to VGX-6150 in treatment failure patients with chronic hepatitis C
Estimated Enrollment: 18
Study Start Date: January 2014
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental: 1mg of DNA/dose
Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
Biological: VGX-6150
Plasmid DNA delivered via IM injection with electroporation
Experimental: Experimental: 3mg of DNA/dose
Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
Biological: VGX-6150
Plasmid DNA delivered via IM injection with electroporation
Experimental: Experimental: 6mg of DNA/dose
Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
INO-3112 Phase I/IIa trials to launch First Half of 2014:
I think we see a partner very shortly for these 2 trials
1. Cervical cancer HPV Type 16/18 Phase I/IIa
2. Head & neck cancer HPV Type 16/18 Phase I/IIa
Oral - Lyn results are expected as well, at some point. Reporting you to ihub (not GNBT board)admins for spamming the board. Trying to make this look like YMB?
Wow man get a grip. I am not this guy. I am also looking forward to oral-lyn results and possible H1N1 tri-fecta.
Inovio is cheap right now but now for long: Pipeline -
• HPV Cervical dysplasia VGX-3100 SynCon® vaccine - Phase II study enrollment completed; top-line data expected in mid-2014 - Flagship.
• HPV Cervical cancer VGX-3100 - Phase I/IIa 1H 2014.
• HPV Head and Neck cancer VGX-3100 - PhaseI/IIa 1H 2014.
• hTERT - Lung and Breast Cancer therapeutic - Initiate phase I clinical trial in 2014
• Hepatitus B - Partnered with Roche - Phase I/IIa 2014.
• Prostate cancer INO-5150 SynCon® vaccine - Roche partnership- Initiate phase I/IIa in 1H 2014
• Hepatitus C - INO-8000-Report data 2015 & International Trials in Korea
• HIV PENNVAX®-B - Phase I - Data published in the Journal of Infectious Diseases in July 2013
• HIV PENNVAX®-B HIV infected subjects. Strong T-Cell response.
• HIV PENNVAX®-G HIV Vaccine - Collaborating with U.S. Army researcher - Phase I enrolled
• HIV PENNVAX®-GP HIV Vaccine - Initiate phase I clinical trial in 1H 2014
• Influenza Universal H5N1 preventive VGX-3400X - Seeking Grant Funding
• Influenza Universal H7N9 preventive - Seeking Grant Funding
• Influenza Seasonal (H5N1 + H1N1) - Seeking Grant Funding
• Influenza Seasonal (H1N1, elderly) - Seeking Grant Funding
• Malaria - Partner MVI/PATH - Phase I/IIa 2014
• MERS - 100% of mice (20 of 20) were able to neutralize or completely block actual infection of MERS virus in the cells, demonstrating the protective potential of this vaccine
We have developed SynCon® vaccines against Ebola & Marburg filoviruses, foot-and-mouth disease (for animals), dengue fever, Chikungunya virus, and other tropical infectious diseases, some which pose potential risk for bioterrorism use.
•Monoclonal Antibody R&D.
Dr. Kim CEO of the year in Korea.
I like that Idea. I have made over 50 grand in INO. Ok I have 35k shares in INO lets see big mouth losers pick in 6 months. He is too coward to pick 1. Putting our money where our mouth is. Lets see the HPV results.
BTW who the heck has time to troll a board in which they are not invested? What a pud.
HPV Due diligence. VGX-3100 Principal Investigator: Cornelia Trimble, MD works for Johns Hopkins University. Inovio study is in good hands.
http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/cervical_dysplasia/treatment.html
"Therapeutic HPV VaccinesThrough the efforts of a team of investigators in the Johns Hopkins Center for Cervical Dysplasia, several clinical trials testing immune therapies for HPV disease are currently open. The development of these HPV-targeted immune therapies, chronicled in over 20 publications in leading biomedical research journals, emerged from a team of translational investigators in three different disciplines: immunology, gynecologic pathology, and gynecology. The initial generation of HPV vaccines involved the use of targeting signals that made HPV antigens more visible to the immune system. In animal models, these vaccines made strong immune responses against HPV. In addition, strategic collaborations with a number of companies are paving the way to the development of combination immunotherapies with even greater potential efficacy. It is our goal to develop a combinatorial HPV immunotherapy approach that could be applied to all women with established HPV infections, that would ultimately eliminate the need for the complex and expensive screening, long-term follow-up, and surgical interventions currently employed to manage HPV disease. The identification of specific HPV antigens makes this disease an ideal model to develop antigen-specific immunotherapies for other chronic viral diseases, such as hepatitis, and ultimately, non-virus-associated cancers."
http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/cervical_dysplasia/research.html
HPV003- Phase II placebo-controlled study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA vaccine) delivered IM followed by electroporation (EP) with CELLECTRA®-5P for the treatment of biopsy-proven CIN2/3 or CIN3 with documented HPV16 or 18 (currently enrolling patients)
OVERVIEW
This study will test the efficacy and safety of VGX-3100 delivered intramuscularly, followed by electroporation in patients with HPV16+ or HPV18+ CIN2/3. Subjects will receive either placebo or VGX-3100 vaccinations at week 0, 4 and 12, prior to a cone or LEEP resection at week 36. There are a total of 12 visits over a period of 88 weeks.
ELIGIBILITY
Healthy females age 18-50 with HPV16 or HPV18+ CIN2/3 or CIN3
Immune competent
Not pregnant or breastfeeding
Informed consent
CONTACT
Mihaela Paradis – 410-502-0512 or mparadis@jhmi.edu
San Antonio Breast Cancer Symposium is next week. Do they enter in late or is it same old GNBT wait till next year excuses.
http://www.bioleaders-forum.com/files/phacilitate_washington_2014_vaccine_brochure.pdf
http://www.bioleaders-forum.com/files/phacilitate_washington_2014_immunotherapy_brochure.pdf
Emerging pathogens: How to face the latest wave of
ID threats with the benefit of past experience? 2.35 Government, regulator and industry perspectives, followed
by roundtable discussion
• Middle East respiratory syndrome coronavirus (MERS-CoV)
– defining the potential threat to global public health
moving forward, and the market opportunities (or lack of
them) for the vaccine industry
- Industry perspective: Lessons learned from SARS vaccine
development on the pros and cons of pursuing novel
pathogens
• H7N9 – how to ensure a speedy and effective response on
a global basis?
Priorities: Public sector & NGO vaccine funding strategies
for specific diseases and technology platforms
9.00 Chair’s introduction
Dr Rajeev Venkayya, Executive Vice President & Head of the
Vaccine Business, Takeda Pharmaceuticals
US Department of Health & Human Services & NIH perspectives,
followed by Q&A
• Outlining ongoing vaccine R&D and technology funding priorities:
- for dengue, H7N9 and other emerging pathogens
- for pre-existing public health threats (including TB, H5N1)
• By what process are these choices made? Where is the ‘tipping
point’ when it comes to allocating funds and resources (or not) –
for example, to a potential pandemic versus an existing public
health threat?
- What’s needed on a regional basis?
- Weighing up technical, financial and ethical challenges
• Is a hexavalent combination vaccine for global use
technically feasible?
- Beyond acellular pertussis – what’s next?
• How to decide upon the division of funds between:
- eradication campaigns for diseases such as polio,
- major global health threats for which vaccines are currently
available in the West (eg. HPV, pneumococcus, measles),
- and major public health threats as yet
• How to decide upon the division of funds between:
- eradication campaigns for diseases such as polio,
- major global health threats for which vaccines are currently
available in the West (eg. HPV, pneumococcus, measles),
- and major public health threats as yet unaddressed by
vaccines, such as HIV and malaria?
Speakers/panellists:
Dr John Boslego, Director, Vaccine Development Global
Program, PATH
Lots of opportunities here.
http://www.bioleaders-forum.com/files/phacilitate_immunotherapy_forum_2014__agenda_for_web__19.11.13.pdf
Cancer vaccines: Learning from past successes and failures to deliver
game-changing efficacy
2.30 Chair’s introduction
Dr Mark Bagarazzi, Chief Medical Officer, Inovio
Industry case studies
Latest clinical data from leading cancer vaccines in development
What progress is being made in developing a viable business model for autologous cancer
vaccines?
What have we learnt in terms of improving the potency of cancer vaccines?
Identifying optimal Phase II , Phase III trial designs and strategies. (Applying flexibility in the
use of randomized Phase II control; end point selection and relevance - short- and long-term;
placebo control for efficacy; use of adaptive and in silico trials to improve data)
Combination development strategies involving the Standard of Care (chemotherapy and
radiotherapy in particular) – sharing key learnings in terms of dosing schedule/sequence of
administration/potential to enhance the immunotherapy (repeat dosing / immunogenicity – how
to test for it clinically?)
Personalized cancer immunotherapy: Given the heterogeneity of cancer AND the immune
system, what do we expect here?
You and ALL your posts are a compilation of bs.
Thanks for the encouragement! I am around 20k+ shares depeding on the chart.